Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)

China · Delayed Price · Currency is CNY

21.63

+0.97 (4.70%)

Aug 3, 2026, 4:00 PM EDT

-28.71% (1Y)

Market Cap	1.19B -28.7%
Revenue (ttm)	162.81M -28.7%
Net Income	-58.72M
EPS	-1.06
Shares Out	55.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.34 (1.57%)
Ex-Dividend Date	n/a

Volume	1,165,010
Open	20.82
Previous Close	20.66
Day's Range	20.52 - 21.70
52-Week Range	17.81 - 36.00
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:688217

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addi... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 336

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688217

Full Company Profile

Financial Performance

In 2025, SHA:688217's revenue was 177.26 million, a decrease of -26.84% compared to the previous year's 242.31 million. Losses were -50.38 million, 219.6% more than in 2024.

Financial Statements